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INTRODUCTION INTRODUCTION
APOBEC3G (3G) and APOBEC3F (3F) are potent inhibitors of HIV-1 infectivity by 
deaminating an inordinate number of cytidines in the intermediary DNA strand (minus) 
following reverse transcription, resulting in excessive guanidine to adenine 
substitutions in the proviral DNA (hypermutation). Hypermutation has been considered 
to only occur in the absence of vif, the viral infectivity protein that complexes with 3G 
and 3F, promoting their ubiquitination and proteasomal degradation. However recent in 
vitro data indicate 3G and 3F are partially resistant to vif
(1,2,3) and this partial resistance 
to vif may explain why G/A substitutions are the most common substitution observed in 
lentiviral DNA. APOBEC3G and -3F preferentially deaminate cytidines in the CCA and 
TC context, respectively 
(4,5) and we used this sequence specificity to investigate the 
contribution of each to HIV-1 G→A substitutions retrospectively in near full-length HIV-
1 proviral DNA sequences from 185 HIV+, antiretroviral naïve participants in the 
Western Australian HIV-1 cohort (6,416 ± 1,998 bases per patient) and their 
subsequent influence on viral load. 
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METHODS METHODS
• Retrospective analysis of 18, 674 G→A substitutions (relative to population 
consensus) in near full-length HIV-1 proviral sequences (6,416 ± 1,998 bases per 
patient) derived from 185 patients. Sequence context of substitutions was assessed by 
comparing frequencies of specific nucleotides at nucleotide positions -2 to +2 relative to 
deamination sites in hypermutated patients versus non-hypermutated patients. 
• Proviral DNA was analysed according to deciles of G→A substitution characteristics by 
ANOVA with multiple comparisons and Bonferroni corrections. 
• Contribution of APOBEC3G allelic variation to hypermutation was assessed by 
comparison of the allele frequencies of patients with >42% frequency of G →A 
substitutions in the GG context (n=8) to a pooled DNA sample (n=200), estimated by 
chromatograph relative peak heights, by Fishers exact test.
• The contribution of functional versus non-functional vif to hypermutation was 
determined by comparing the presence of in-frame stop codons to G→A load and 
number of G→A substitutions in the TAG context.
CONCLUSIONS CONCLUSIONS
• The G →A load is bimodally distributed around mean values of 4% and 12% of G content. 
• At least 40% of the sampled cohort had evidence of APOBEC3G-mediated G→A mutations with    
a TGG context preference. 
• APOBEC3G, rather than APOBEC3F, was the dominant contributor to G→A hypermutation.
• Participants harbouring proviral DNA with >10.6% G→A load (20% of sampled cohort) had 
significantly reduced viral load compared to those with proviral DNA with <10.6% G→A load. 
•The influence of G→A hypermutation on viral load was independent of that exerted by HLA-B57,    
-B58 and/or CCR5∆32 alleles.
•Vif in-frame stop codons and 3 APOBEC3G non-coding SNPs were associated with 
hypermutation. 
Results Results
• Overall, proviral sequences had 1.83 ± 1.05-fold more G→A mutations than A→G mutations (range 1.0 - 8.7), accounted 
for 20.4 ± 5.8% (range 12.9% - 48.9%) of all mutations, and 7.2 ± 4.3% (range 2.9% - 28.2%) of consensus G’s were 
mutated to A.
• The frequency of consensus Gs mutated to A appeared bimodally distributed at approximately 4% and 12%.
• Each mutational characteristic was significantly positively correlated to the frequency of G→A mutations specifically in the 
TGG context (r2 0.737-0.830, p<0.001), GG context (r2 0.436-0.512, all p<0.001), TG context (r2 0.221-0.382, all p<0.003), 
and negatively correlated to viral load (r2 -0.178 - -0.315, p<0.015). 
• A significant increase in the frequency of G→A mutations in the GG and TG contexts occurred in the 60
th percentile based 
on consensus Gs mutated to A values (GG 29.2% vs 20.4%, p=0.028; TG 25.5% vs 22.1%, p=0.024). 
• A significant increase in the number of G→A mutations the TGG context was evident at the 20
th percentile (0.06 ± 0.04 vs
0.04 ± 0.02 100
-1
bp), the 60
th percentile (0.11 ± 0.08 vs 0.06 ± 0.04 100
-1
bp, p=0.019) and again at the 90
th percentile (0.43 
± 0.34 vs 0.15 ± 0.11 100
-1
bp, p=0.003) based on number of consensus Gs mutated to A values or G→A: A→G values (20
th
0.08 ± 0.05 vs 0.04 ± 0.03 100
-1
bp, p<0.001; 60th 0.11 ± 0.08 vs 0.08 ± 0.05 100
-1
bp, p=0.013; 90
th 0.48 ± 0.31 vs 0.11 ±
0.08 100
-1
bp, p<0.001).
• A significant increase in the number of G→A mutations the TGG context was evident at the 40
th percentile (0.09 ± 0.07 vs
0.06 ± 0.05 100
-1
bp, p=0.002) and 90
th percentile (0.48 ± 0.30 vs 0.09 ± 0.07 100
-1
bp, p<0.001) based on proportion of G→A 
mutations relative to all other mutations. 
• A significant reduction in viral load was evident at the 80
th percentile based on G→A load (log10 4.37 vs 4.94, p=0.003).
• In multivariate linear regression analysis of viral load including protective host factors HLA-B27, -B57, -B58 and CCR5∆32, 
G→A load (β -0.337, P<0.001), CCR5∆32 (β -0.207, P=0.003) and HLA-B57 (β -0.153, P=0.027) remained highly significant. 
• Significant differences in the allele frequencies of 3 non-coding APOBEC3G SNPs were observed in 8 patients harbouring 
hypermutated proviral sequence compared to a pooled DNA control sample (n=200), although the functional significance is 
unclear.
• 21 (12.7%) of participants had stop codons in the vif ORF. These participants had significantly higher G→A substitution 
characteristics (all p<0.002), frequency of G→A substitutions in the TAG (0.38 ± 0.34 vs 0.09 ± 0.08 100
-1
bp, p=0.001) and 
GG (33.0 ± 14.0% vs 22.8 ± 8.1%, p=0.003) contexts and significantly lower viral load (4.46 ± 0.66 vs 4.90 ± 0.81, p=0.020) 
than those without stop codons in the vif ORF. Interstingly, the G→A substitution rate of participants with defective vif (2.73 ±
0.38 100
-1 bp) reflects that obtained in vitro utilising wild type 3G and ∆vif HIV-1 virions (2.98 100
-1 bp)
(6)
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ABSTRACT ABSTRACT
Background: Background: Editing of HIV-1 DNA and RNA by APOBEC family cytidine deaminases to produce 
hypermutated sequences has emerged as a potent host antiviral response. This effect is modulated by the 
presence of Vif  that opposes APOBEC activity.  Here we examine the clinical relevance and extent of 
hypermutation within proviral DNA, the sequence context of G→A hypermutation, and the contributions of 
genetic variation in host APOBEC3G and HIV-1 Vif.
Methods: Methods: Full-length HIV-1 proviral DNA sequences from 185 antiretroviral-naive patients were examined, 
including 18,136 G→A substitutions. Hypermutation was classified by 3 criteria and validated by analyses of 
the population distribution of G→A substitutions. In individuals with hypermutation, APOBEC3G exonic and 
putative 5’ regulatory region sequences were compared with control data (n=200). Analyses of Vif amino acid 
sequences were also undertaken, and pre-treatment viral load (VL) was assessed in group comparisons.
Results: Results: All 3 criteria for hypermutation were satisfied in sequences obtained from 8 (4.3%) individuals, 
with 1 criterion met by 20 (10.8%). VL (log10copies/mL) was significantly lower in the hypermutated group 
using the broader definition (4.25 v 4.89, P=0.01) but not the restrictive definition (4.56 v 4.83, P=0.36). 
Compared with background rates of 6.1±2.5% G→A substitution, hypermutated sequences demonstrated 
20.3±6.2% G→A substitutions by a restrictive definition (broad = 16.0±5.5%) (both P<0.001). Hypermutated 
G→A substitutions demonstrated a preference for G at the +1 position (45% v 23%) and enrichment of T at 
position -1 (34% v 23%), (P<0.001) consistent with an APOBEC3G plus strand DNA target motif TGG 
(corresponding to CCA on the minus strand DNA). Expected strong selection against CpG dinucleotides was 
also universally noted. APOBEC3G sequencing of the 8 subjects with definite hypermutation revealed no 
novel variants. Analysis of Vif  sequence however, revealed that 100% of the hypermutated group had 
defective Vif, defined as absence of appropriate start and stop codons and/or presence of in-frame stop 
codons.
Conclusions: Conclusions: This in vivo study demonstrates that hypermutation is not infrequent at a population level 
and is associated with lower pre-treatment viral load, in keeping with a host antiviral effect potentially 
mediated by APOBEC3G. 
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Vif in-frame 
stop codons
No Vif in-frame 
stop codons
Allele 1 Allele 2 Allele 2 A1A1 A1A2 A2A2
7291971 0.60 0.40 0.40 233
6519166 0.70 0.30 0.31 251
57507473 0.50 0.50 0.28 152
12158985
>0.90 <0.10 0.09 710
0.80 0.20 - 224
2294367
0.60 0.40 0.51 440
-
>0.90 <0.10 0.07 6 2 0
3091374
0.70 0.30 0.34 251
5757468
0.60 0.40 0.42 233
-
>0.90 <0.10 - 6 2 0
5757471
0.50 0.50 233
17537574
0.70 0.30 2 5 1
17537581
>0.90 <0.10 6 2 0
APOBEC3G Allele Frequencies
rs#
Control (n=200) Hypermutated (n=8)
Position
-962
-959
-90
2664
2809*
F119F
8170
8391
9032
9062
8169
-
-
-
5757472
3891126
Allele 1 Allele 2
0.44 0.56
0.56 0.44
0.44 0.56
0.94 0.06
0.38 0.63
0.75 0.25
0.88 0.12
0.56 0.44
0.44 0.56
0.88 0.12
0.44 0.56
0.56 0.44
0.88 0.12
Do et al, 2005
12160242
9607609
5757465
2294366
9076* 5757467
9077
9078
Q275E
11412
11444
11626
+22*
+28
+219
+430
0.70 0.30
>0.90 <0.10
>0.90 <0.10
>0.90 <0.10
>0.90 <0.10
0.50 0.50
0.70 0.30
0.50 0.50
>0.90 <0.10
-
-
-
-
-
-
-
-
-
-
053 0.31 0.69
620 0.88 0.012
710 0.94 0.06
620 0.88 0.12
620 0.88 0.12
510 0.92 0.06
800 1.00 0.0
152 0.44 0.56
620 0.88 0.12
0.12
0.07
6 Newman et al, Curr. Biol.  15, 2 (2005). 
C-145
A% C% G% T% A% C% G% T%
%TAG of G→A 
substitutions TAG/100 bases LOGVL
<0 56.5 4.9 19.8 18.8 39.0 21.0 20.3 19.6 5.6 0.0394 5.291
1 58.1 6.9 14.1 21.0 37.5 22.7 18.7 21.1 4.8 0.0388 5.112
2 52.6 7.7 16.3 23.4 35.8 21.5 22.1 20.7 6.9 0.0645 5.145
3 57.0 7.2 14.7 21.1 40.4 20.6 20.2 18.9 6.0 0.0610 4.835
4 51.4 8.0 16.7 23.9 36.1 23.4 21.0 19.4 5.9 0.0633 4.719
5 52.6 7.6 15.7 24.2 35.2 21.8 20.3 22.8 5.1 0.0614 4.972
6 49.5 7.4 17.6 25.5 37.7 17.6 28.2 16.5 8.0 0.1139 4.795
7 52.2 7.8 16.5 23.5 35.9 17.5 29.7 16.9 8.7 0.1675 4.687
8 51.7 8.1 17.4 22.8 35.1 20.7 26.6 17.6 6.7 0.1778 4.385
9 51.1 6.2 15.5 27.2 41.2 13.8 32.6 12.3 11.2 0.4264 4.244
Total 53.3 7.2 16.4 23.1 37.4 20.1 24.0 18.6 6.9 0.1209 4.818
f value 2.755 1.457 1.291 2.571 1.286 3.918 5.527 4.276 3.052 16.319 3.512
p value 0.005 0.167 0.245 0.010 0.247 <0.001 <0.001 <0.001 0.002 <0.001 0.001
G→A Mutational Load Characteristics
G→A load
Decile
-1 position +1 position
G→A load
<3.9%
4.2%
4.6%
4.9%
5.2%
5.6%
10.6%
12.0%
≥12.0%
-
-
-
7.9%